Synthesis and anticancer activity of brefeldin A ester derivatives
- PMID: 16789745
- DOI: 10.1021/jm0602817
Synthesis and anticancer activity of brefeldin A ester derivatives
Abstract
Ester derivatives of brefeldin A (BFA) were synthesized to determine which of its two hydroxyl groups could be modified while still maintaining biological activity. The compounds were tested for antiproliferative activity in the National Cancer Institute's 60 cancer cell line screen. Monoderivatization at the C4 and C7 alcohols was tolerated, yielding biologically active compounds, whereas the analogues derivatized at both positions were the least active in the series. Molecular modeling of the analogues revealed that both the C4 and C7 derivatives were well tolerated at the interface between ARF1 and its guanine nucleotide exchange factor ARNO. The Golgi-disruptive properties of the analogues were determined using fluorescence imaging assays. The BFA ester conjugates synthesized in this study were cytotoxic to cancer cells, and we have shown that the disruption of the Golgi complex is not necessary for cytotoxicity. The brefeldin A ester derivatives are potential anticancer agents.
Similar articles
-
Niacin Ester Derivative of Brefeldin A as a Potential Dual-Target Arf1/BMX Inhibitor for Bladder Cancer.J Nat Prod. 2025 Mar 28;88(3):830-841. doi: 10.1021/acs.jnatprod.5c00086. Epub 2025 Mar 14. J Nat Prod. 2025. PMID: 40085024
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2. Cochrane Database Syst Rev. 2017. Update in: Cochrane Database Syst Rev. 2020 Jan 9;1:CD011535. doi: 10.1002/14651858.CD011535.pub3. PMID: 29271481 Free PMC article. Updated.
-
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2022 May 23;5:CD011535. doi: 10.1002/14651858.CD011535.pub5. PMID: 33871055 Free PMC article. Updated.
-
Synthesis of Novel Derivatives of 4,6-Diarylpyrimidines and Dihydro-Pyrimidin-4-one and In Silico Screening of Their Anticancer Activity.Curr Org Synth. 2025;22(4):556-567. doi: 10.2174/0115701794356958241024082646. Curr Org Synth. 2025. PMID: 40420790 Free PMC article.
-
Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer.Future Med Chem. 2025 Jan;17(1):35-58. doi: 10.1080/17568919.2024.2437972. Epub 2024 Dec 18. Future Med Chem. 2025. PMID: 39691063
Cited by
-
Anti-Tumor Secondary Metabolites Originating from Fungi in the South China Sea's Mangrove Ecosystem.Bioengineering (Basel). 2022 Dec 6;9(12):776. doi: 10.3390/bioengineering9120776. Bioengineering (Basel). 2022. PMID: 36550982 Free PMC article. Review.
-
Recent Synthesis and Discovery of Brefeldin A Analogs.Mar Drugs. 2018 Apr 18;16(4):133. doi: 10.3390/md16040133. Mar Drugs. 2018. PMID: 29670019 Free PMC article. Review.
-
Design and Synthesis of Arf1-Targeting γ-Dipeptides as Potential Agents against Head and Neck Squamous Cell Carcinoma.Cells. 2020 Jan 24;9(2):286. doi: 10.3390/cells9020286. Cells. 2020. PMID: 31991585 Free PMC article.
-
Growth inhibition of androgen-responsive prostate cancer cells with brefeldin A targeting cell cycle and androgen receptor.J Biomed Sci. 2010 Jan 26;17(1):5. doi: 10.1186/1423-0127-17-5. J Biomed Sci. 2010. PMID: 20102617 Free PMC article.
-
Drugging the Small GTPase Pathways in Cancer Treatment: Promises and Challenges.Cells. 2019 Mar 16;8(3):255. doi: 10.3390/cells8030255. Cells. 2019. PMID: 30884855 Free PMC article. Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous